Related Experiment Videos
Fibrinolysis and thrombosis
1Department of Molecular & Cell Biology, University of Aberdeen, Marischal College, UK.
Bailliere'S Clinical Haematology
|September 1, 1994
Summary
Defective fibrinolysis, the breakdown of blood clots, is linked to thrombus formation. Enhancing the body's natural fibrinolytic mechanisms could prevent and treat thrombosis.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Hematology
Background:
- Venous and arterial thrombi are rich in fibrin.
- Defective fibrinolysis may contribute to thrombus formation and persistence.
- Thrombi can evade lysis by incorporating inhibitors like PAI-1 and alpha 2-antiplasmin.
Purpose of the Study:
- To explore the role of fibrinolysis in thrombosis and atherosclerosis.
- To investigate the potential of enhancing fibrinolytic mechanisms for therapeutic benefit.
Main Methods:
- Review of existing evidence on fibrinolytic mechanisms and thrombosis.
- Analysis of the composition of arterial and venous thrombi.
- Evaluation of the efficacy of thrombolytic agents.
Main Results:
- Fibrin is a key component of both venous and arterial thrombi.
- Evidence suggests a causal link between defective fibrinolysis and thrombosis.
- Fibrinolytic mechanisms may also influence atherosclerotic lesion development.
- Thrombolytic agents are effective when administered early.
Conclusions:
- Defective fibrinolysis is implicated in the development and persistence of thrombi.
- Inhibitors within thrombi hinder natural clot breakdown.
- Future strategies may focus on enhancing endogenous fibrinolysis to prevent and treat thrombosis.
- Targeting fibrinolytic mechanisms offers a promising therapeutic avenue.